For too long patients and healthcare professionals have accepted chemotherapy’s poor efficacy and unwanted side effects. But that is changing as NuCana’s transformative technology is pioneering a new era in oncology. Superior chemotherapy medicines with greater activity and a cleaner profile promise new hope for cancer patients.
Our name, "NuCana", is derived from "New Cancer Agents” and “Nucleotide Analogs”. It represents both our objective of inventing, developing and bringing to market truly novel, transformational medicines, as well as the proprietary medicinal chemistry platform upon which they are built. Our medicines are completely new cancer treatments. Cancer cells can already evade or develop resistance to established chemotherapy drugs; this limits their efficacy and increases toxicity. NuCana’s agents are specifically designed to overcome this cancer cell evasion and resistance. We have already seen how patients with advanced cancers can benefit from our transformative approach.
We call our new medicines, ProTides. Each one is different but they all share a unique chemical transformation, which the inventor, the late Professor Chris McGuigan, termed the ‘phosphoramidate’ moiety. This confers very specific characteristics and dramatically alters the dynamics of these new medicines. This medicinal chemistry approach led to the development of the anti-viral drugs Sovaldi® and TAF®, the two most successful drug launches in the history of the pharmaceutical industry.
We have rapidly advanced our first two ProTides to the clinic, with a third ProTide planned to enter Phase I studies in 2018. Our lead compound, Acelarin, is in Phase I, II and III studies and our second ProTide, NUC-3373, is in a Phase I study. The clinical results we have seen to date have been highly promising and we are extremely encouraged by what has been achieved. This spurs us on to expedite the development of these important new agents.
We have the expertise to fully exploit the advantages of this revolutionary technology platform. Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.
Rapidly advance development of Acelarin as the first-in-class nucleotide analog for the treatment of patients with cancer
Accelerate development of NUC-3373 to replace 5-FU as the standard of care for the treatment of a variety of common cancers
Introduce NUC-7738 into clinical studies
Leverage our proprietary ProTide technology platform to develop additional product candidates